---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003945"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:18:42.514534+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atara cuts 25% of workforce, restructures to focus on CAR-T; CMO departs

## Summary
- Workforce reduction of ~25% (approx. 56 employees) expected to complete by May 2024; severance costs ~$4.5M.
- CMO Manher Joshi to depart Feb 2, 2024; receives 12 months severance, $3k/month consulting fee, $185k tab-cel BLA milestone.
- Restructuring plus $27M upfront from Pierre Fabre pact and existing cash expected to fund operations into 2027.
- Tab-cel BLA on track for Q2 2024 submission; pivotal ALLELE study showed ORR 49% (p<0.0001).
- IND for ATA3219 in Lupus Nephritis planned Q1 2024; preliminary clinical data in lymphoma expected H2 2024.

## SEC filing metadata
- accession: 0001193125-24-003945
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/0001193125-24-003945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/d703405d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003945
- JSON: https://secwatch.observer/filing/0001193125-24-003945.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003945.txt

## Key facts
- Executive change
  Manher (AJ) Joshi was terminated as Executive Vice President, Chief Medical Officer at Atara Biotherapeutics, Inc..
  - Action: terminated
  - Role: Executive Vice President, Chief Medical Officer
  source text: On January 8, 2024, the Company announced that the employment of Manher (AJ) Joshi, the Company’s Executive Vice President, Chief Medical Officer, would terminate effective as of February 2, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/0001193125-24-003945-index.htm
- Restructurings & Charges
  Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $4.5 million (approximately 25% of its current employees).
  - Type: restructuring
  - Charge: approximately $4.5 million
  - Headcount: approximately 25% of its current employees
  source text: On January 8, 2024, Atara Biotherapeutics, Inc. (the “Company”) announced a reduction in its workforce that will impact approximately 25% of its current employees. The Company expects to substantially complete the workforce reduction by May 2024. The Company expects to recognize approximately $4.5 million in total for severance and related benefits for employees laid off under the reduction in force.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312524003945/0001193125-24-003945-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.